Please ensure Javascript is enabled for purposes of website accessibility

Why MannKind Stock Is Crushing It Today

By Keith Speights – Updated Jun 15, 2020 at 3:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked the biotech's presentations at a major diabetes conference.

What happened

Shares of MannKind Corporation (NASDAQ: MNKD) were soaring 13% higher as of 3:32 p.m. EDT on Monday. The big jump came after the company presented new data from clinical studies for inhaled insulin product Afrezza at the American Diabetes Association's 80th Scientific Sessions conference.

So what

MannKind had good news all around at the ADA's virtual conference. The company presented a post hoc analysis from four studies that evaluated Afrezza in patients with Type 1 diabetes. This analysis showed that Afrezza can be safely and effectively dosed at 1.5 to two times the level of injected mealtime insulin.

Doctor writing diabetes

Image source: Getty Images.

Another analysis presented at the ADA conference demonstrated that treatment with Afrezza is associated with weight loss in patients with Type 2 diabetes. MannKind also presented results from a two-year safety study that showed significant changes in forced expiratory volume 1 (FEV1), a measure of pulmonary function, were uncommon and generally transient during treatment with Afrezza.

The big takeaway for MannKind was that all of its ADA presentations underscored the effectiveness and safety of Afrezza. Positive results at the important scientific conference could translate into higher sales for the drug if physicians gain confidence in prescribing Afrezza. 

Now what

MannKind reported net sales for Afrezza in the first quarter of 2020 totaled $8 million. While that reflected a 58% year-over-year jump, significantly more growth is needed for the company to achieve profitability. Still, though, the biotech stock is on a roll so far in 2020 with a year-to-date gain of more than 20%. Today's good news could help MannKind keep its momentum going.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.